+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020

  • ID: 5212222
  • Report
  • November 2020
  • Region: Global
  • 96 pages
  • GlobalData

FEATURED COMPANIES

  • Abbott Diagnostics
  • Bioprognos SL
  • Glycotest Inc
  • IntegraGen SA
  • Northwestern University
  • ProMIS Neurosciences Inc
Summary

The publisher's Medical Devices sector report, “Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Liver Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Liver Cancer Diagnostic Tests include assays of mostly antibodies released in response to a liver cancer and cancer-causing proteins.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Liver Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Liver Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Liver Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Diagnostics
  • Bioprognos SL
  • Glycotest Inc
  • IntegraGen SA
  • Northwestern University
  • ProMIS Neurosciences Inc
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.1 Liver Cancer Diagnostic Tests Overview

3 Products under Development
3.1 Liver Cancer - Pipeline Products by Stage of Development
3.2 Liver Cancer - Pipeline Products by Territory
3.3 Liver Cancer - Pipeline Products by Regulatory Path
3.4 Liver Cancer - Pipeline Products by Estimated Approval Date
3.5 Liver Cancer - Ongoing Clinical Trials

4 Liver Cancer - Pipeline Products under Development by Companies
4.1 Liver Cancer Companies - Pipeline Products by Stage of Development
4.2 Liver Cancer - Pipeline Products by Stage of Development

5 Liver Cancer Companies and Product Overview

6 Liver Cancer- Recent Developments
6.1 Sep 30, 2020: Skoltech scientists discovered a new biomarker for liver cancer diagnosis
6.2 Jul 30, 2020: Blueprint Medicines reports second quarter 2020 financial results
6.3 Jun 24, 2020: Novel radiotracer proves advantageous for imaging neuroendocrine tumor patients with liver-dominant disease
6.4 Jun 15, 2020: Study demonstrates feasibility of hologram technology in liver tumor ablation
6.5 Jun 02, 2020: Pfizer establishes new program to support continued biotechnology innovation
6.6 May 12, 2020: National Cancer Institute renews Jackson Laboratory’s Cancer Center Designation
6.7 Feb 27, 2020: James Quincey elected to Pfizer’s board of directors
6.8 Feb 14, 2020: Pfizer: Appointment of Mr. Samir Kazi as an executive director
6.9 Feb 14, 2020: Pfizer: Resignation of Mr. Vivek Dhariwal
6.10 Feb 13, 2020: Blueprint Medicines reports fourth quarter and full year 2019 financial results
6.11 Jan 28, 2020: Pfizer reports fourth-quarter and full-year 2019 results
6.12 Jan 27, 2020: PerkinElmer announces financial results for the fourth quarter
6.13 Jan 13, 2020: Blueprint Medicines announces 2020 corporate goals
6.14 Jan 02, 2020: Pfizer, Sanofi and GlaxoSmithKline plan to increase US drug prices in 2020
6.15 Dec 18, 2019: Pfizer and Mylan announce two future Viatris board members
6.16 Dec 16, 2019: Pfizer declares first-quarter 2020 dividend and announces upcoming investor day to highlight strength of innovative R&D pipeline

7 Appendix
7.1 Methodology
7.2 About the Publisher
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Liver Cancer - Pipeline Products by Stage of Development
Table 2: Liver Cancer - Pipeline Products by Territory
Table 3: Liver Cancer - Pipeline Products by Regulatory Path
Table 4: Liver Cancer - Pipeline Products by Estimated Approval Date
Table 5: Liver Cancer - Ongoing Clinical Trials
Table 6: Liver Cancer Companies - Pipeline Products by Stage of Development
Table 7: Liver Cancer - Pipeline Products by Stage of Development
Table 8: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
Table 9: ARCHITECT c16000 System - PIVKA Assay - Product Status
Table 10: ARCHITECT c16000 System - PIVKA Assay - Product Description
Table 11: ARCHITECT c4000 System - PIVKA Assay - Product Status
Table 12: ARCHITECT c4000 System - PIVKA Assay - Product Description
Table 13: ARCHITECT c8000 System - PIVKA Assay - Product Status
Table 14: ARCHITECT c8000 System - PIVKA Assay - Product Description
Table 15: ARCHITECT ci16200 Integrated System - PIVKA Assay - Product Status
Table 16: ARCHITECT ci16200 Integrated System - PIVKA Assay - Product Description
Table 17: ARCHITECT ci4100 Integrated System - PIVKA Assay - Product Status
Table 18: ARCHITECT ci4100 Integrated System - PIVKA Assay - Product Description
Table 19: ARCHITECT ci8200 Integrated System - PIVKA Assay - Product Status
Table 20: ARCHITECT ci8200 Integrated System - PIVKA Assay - Product Description
Table 21: ARCHITECT i4000SR System - PIVKA II Assay - Product Status
Table 22: ARCHITECT i4000SR System - PIVKA II Assay - Product Description
Table 23: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 24: Biomarker Test - Liver Cancer - Product Status
Table 25: Biomarker Test - Liver Cancer - Product Description
Table 26: AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview
Table 27: Multiplexed Detection - Des-Carboxy Prothrombin - Product Status
Table 28: Multiplexed Detection - Des-Carboxy Prothrombin - Product Description
Table 29: Multiplexed Detection - Matrix metalloproteinase 1 - Product Status
Table 30: Multiplexed Detection - Matrix metalloproteinase 1 - Product Description
Table 31: Multiplexed Detection - Procollagen type III N-terminal peptide - Product Status
Table 32: Multiplexed Detection - Procollagen type III N-terminal peptide - Product Description
Table 33: BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 34: Biomarker Assay - Hepatocellular Cancer - Product Status
Table 35: Biomarker Assay - Hepatocellular Cancer - Product Description
Table 36: Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview
Table 37: MBDAA Liver Cancer Test - Product Status
Table 38: MBDAA Liver Cancer Test - Product Description
Table 39: China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 40: Diagnostic Kit - Liver Cancer - Product Status
Table 41: Diagnostic Kit - Liver Cancer - Product Description
Table 42: Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview
Table 43: HCC Molecular Marker Assay - Product Status
Table 44: HCC Molecular Marker Assay - Product Description
Table 45: Oxidated APO-A1 Assay - Product Status
Table 46: Oxidated APO-A1 Assay - Product Description
Table 47: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 48: DNA Biomarkers - Hepatocellular Carcinoma - Product Status
Table 49: DNA Biomarkers - Hepatocellular Carcinoma - Product Description
Table 50: Liquid Biopsy Test - Liver Cancer - Product Status
Table 51: Liquid Biopsy Test - Liver Cancer - Product Description
Table 52: German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview
Table 53: RAGE Based Diagnostic Assay - Liver Cancer - Product Status
Table 54: RAGE Based Diagnostic Assay - Liver Cancer - Product Description

List of Figures
Figure 1: Liver Cancer - Pipeline Products by Stage of Development
Figure 2: Liver Cancer - Pipeline Products by Territory
Figure 3: Liver Cancer - Pipeline Products by Regulatory Path
Figure 4: Liver Cancer - Pipeline Products by Estimated Approval Date
Figure 5: Liver Cancer - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
  • Abbott Diagnostics
  • Abcodia Ltd
  • AXO Science SAS
  • BioMark Technologies Inc
  • Bioprognos SL
  • China Sky One Medical Inc
  • Digna Biotech SL
  • Exact Sciences Corp
  • German Cancer Research Center
  • Glycotest Inc
  • Glympse Bio Inc
  • ImCare Biotech LLC
  • Imperial College London
  • IntegraGen SA
  • IPDx Immunoprofiling Diagnostics GmbH
  • JBS Science Inc
  • Matrix-Bio Inc
  • MDNA Life Sciences Inc
  • Medical University of South Carolina
  • Medical University of Vienna
  • Memorial Sloan Kettering Cancer Center
  • NanoString Technologies Inc
  • Northwestern University
  • Numares AG
  • Oncimmune (USA) LLC
  • Orion Genomics LLC
  • PleX Diagnostics Inc (Inactive)
  • ProMIS Neurosciences Inc
  • Proplex Technologies Llc
  • Proteome Sciences Plc
  • Roche Diagnostics International Ltd
  • University of Hong Kong
  • University of Louisville
  • University of Rochester
  • Ventana Medical Systems Inc
  • Viomics Inc.
  • XEPTAGEN SpA
  • Ymir Genomics LLC.
Note: Product cover images may vary from those shown
Adroll
adroll